7 research outputs found
Melphalan resistance gene index validation by clinical outcome.
<p>The individual RIs were assigned from gene expression data of the HOVON 65/GMMG-HD4 trial dividing tumor samples into groups of sensitive patients with low 0–25% RI, intermediate RI from 25–75% and resistant patients with the highest 75–100% RI. The impact of this assignment was subsequently evaluated with respect to PFS and overall OS as illustrated by log relative hazard for PFS (1A) and OS (1B) as a function of the individual RI levels. The P-values are the maximum likelihood tests for no RCS-association between log Relative Hazard and the RI and the dashed lines represent 95% confidence intervals. A landmark Kaplan-Meier analysis was performed from the time of HDM and we found that resistant, intermediate and sensitive patient groups had a median PFS of 18, 32 and 28 months, respectively (1C). The OS for the resistant group had a median of 45 months but not reached for the intermediate and resistant groups (1D) following a median observation time of 38 months. The P-values are the log-rank-test results for no difference between the estimated survival curves.</p
Univariate and multivariate Cox proportional hazard models.
<p>The sensitive and intermediate RI groups were merged into a common non-resistant group of patients. The redefined non-resistant (RI 0–75%) and resistant (RI 75–100%) groups were analysed by univariate (P-value  = 0.003 for PFS and P-value  = 0.00089 for OS) as well as a multivariate Cox proportional hazard models documenting an association with PFS and OS (P-value of 0.0063 and 0.0025), independent of age, sex and ISS staging. The appropriateness of the Cox proportional hazard models using the dichotomized resistance index was checked using cumulative martingale residuals.</p
The poor diagnostic accuracy illustrated by ROC curves.
<p>The diagnostic accuracy of the RI to predict the PFS and OS was evaluated by ROC curves. The true positive rate (sensitivity) was plotted as a function of the false positive rate (1- specificity) for a series of time dependent cut-off points illustrating the level of discrimination is quantified by area under curve (AUC) for OS and PFS being poor between 60–70%.</p
Summary of the stepwise development, adjustment and validation of the resistance gene list.
<p>Numbers relate to step 1–6 as illustrated in the figure. 1) First, The analysis starts by identification of candidate biomarkers by a sparse partial least squares algorithm (SPLS) to build a predictive gene list based on correlations with the GI50 values of the cell line panel, regarded as <i>“biomarker discovery”</i>. 2) Second, the candidate genes were trained to ensure weighted expression in the myeloma data set from the patient cohort in the clinical trial MRC Myeloma IX, to derive a gene signature model, predictive of resistance to melphalan – a step which is regarded as <i>biomarker weighting</i>. The weighting was performed by multivariate Cox regression with PFS as dependent variable and gene expression of the 19 genes as independent variables resulting in a weighted gene signature. 3) The weighted melphalan resistance gene signature is used to define a melphalan RI. 4) The signature is used to classify each tumour from the clinical trial HOVON65/GMMG-HD4 based on the individual GEP data. 5) The RIs were defined to be the linear predictor of the multivariate Cox regression, i.e. calculated for each individual clinical sample by a linear combination of the 19 gene expressions using the weights from the multivariate Cox regression model. 6) Finally, the molecular prediction of resistance to melphalan therapy was compared to the actual observed PFS and OS. – a step regarded as <i>implementation and evaluation</i>.</p
The melphalan RI in patients treated without HDM.
<p>Illustration of the negative validation of the approach in a data set from156 relapsed MM patients treated without HDM by inclusion into the APEX trial (18) that compared single-agent bortezomib to high-dose dexamethasone. The individual RIs were assigned from each patients' gene expression data of the APEX trial dividing tumor samples into groups of sensitive patients with the low 0–25% RI, intermediate RI between 25–75% and resistant patients with the highest 75–100% RI. The impact of this assignment was subsequently evaluated with respects to PFS and overall OS as illustrated by log relative hazard for PFS (5A) and OS (5B) as a function of the individual RI levels. The P-values are the maximum likelihood tests for no RCS-association between log Relative Hazard and the RI and the dashed lines represent 95% confidence intervals. A landmark Kaplan-Meier analysis was performed from the time of treatment start which found that resistant, intermediate and sensitive patient groups had no significant differences with respect to the prediction of PFS as well as OS from time of relapse therapy. The P-values are the log-rank-test results for no difference in survival curves.</p
The melphalan RI differ between TC classes.
<p>The translocation and cyclin D defined TC classification involving early oncogenic events were applied to the HOVON65/GMMG-HD4 data set and in panel A) each of the 8 classes of tumours showed different melphalan RI levels (P-value  = 0.00025). In panel B) these classes were grouped into two groups with good or poor prognosis with different melphalan RI levels (P-value  = 0.0028).</p
Characterisation of the clinical trial data sets.
<p>Comparison of the two independent HOVON65/GMMG-HD4 and MRC Myeloma IX cohorts with respect to demographic data, ISS staging, TC classification and time to disease progression (PFS) suggesting that clinical expression of resistance was identical. Both trials contained high dose melphalan as a mainstay in the standard therapy for all patients enrolled.</p><p>VAD = Induction with vincristine, adriamycin and dexamethasone. PAD = Induction with bortezomib, adriamycin and dexamethasone. CVAD = Induction with cyclophosphamide, vincristine, doxorubicin and dexamethasone. CTD = Induction with cyclophosphamide, thalidomide and dexamethasone.</p